Hemodialysis for acute kidney injury

Series
Nephrology and Urology
Status
Published
Date
Number of report
079

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for use of hemodialysis as treatment for acute kidney injury. The analysis will cover adult patients only.

Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations). 

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of equipment of hemodialysis for acute kidney injury:

  • Allmed Group (POLYPURE, HF)
  • Asahi Kasei Medical (MDS-101, APS, Rexeed, ViE, KF-201, Cureflo)
  • B. Braun (OMNI, Diapact CRRT, OMNIfilter, Haemoselect, Diacap, Dialog iQ, Xevonta, Diacap Pro)
  • Baxter (Theranova, Prismaflex, Prismax, Phoenix X36, Polyflux 6H, Revaclear, Artis Physio)
  • Bellco/Medtronic (SIMPLY BEYOND, AMPLYA, CARPEDIEM)
  • Biolight Meditech (D-30, DTB-100F, DTB-100)
  • CR Bard/ BD (Decathlon, Equistream, Glidepath, Hemosplit, Hickman, Reliance, Soft-cell, Power-trialysis, DuoGlide, Brevia, Niagara)
  • Dialife Group (Diadvance)
  • Informed (HF440)
  • Farmasol (Dialyzer, Catridge)
  • Kawasumi Laboratories (Dialyzers)
  • Fresenius (multiFiltratePRO, multiFiltrate)
  • Landwind Medical (AISO-3038, JHM-2028A, JHM-2028M, JH-4048, JH-5058)
  • Medivators/Cantel
  • Nikkiso (Aquarius, DBB-EXA, DBB-07, DBB-06, DBB-27, FDX, FDY)
  • Nipro Medical (Surdial-X, Surdial – 55Plus, Elisio, Sureflux, Solacea)
  • Medica (ACUSmart, Smartflux)
  • Serumwerk Bernburg (Dialyzers, cartridges)
  • SWS Medical (SWS-6000, SWS-4000, SWS-5000)
  • Toray Medical (TQS-88, TR-8000)
  • Outset Medical (Tablo)

Table of content is not available at the moment. Report is still ongoing.

28

Mar 2022

In March 2022, NHS England and NHS Improvement published the MedTech Funding Mandate (MTFM) policy for 2022/23, which will come into force on April 01, 2022. The MTFM launched in 2021 to support NICE-approved and cost-saving devices, diagnostics, and digital products. Commissioners must fund technologies included in MTFM.

Read more

14

Feb 2022

On January 28, 2022, the Institute for the Hospital Remuneration System (InEK) has published the list of the requests for innovation funding (NUB) that were submitted by the hospitals in 2021. The medical technologies belonging to the cardiovascular, ENT, eHealth, gastrointestinal, neuromodulation, neurovascular, orthopedic, and other technology groups obtained positive status 1.

Read more

01

Feb 2022

At the beginning of January 2022, the INAMI published a convention for 2022-2023 related to the financing of dialysis. The convention regulates the modalities of reimbursement for dialysis of patients with chronic renal failure.

Read more

31

Jan 2022

On January 20, 2022, the Academy of Medical Royal Colleges (AoMRC) launched a consultation on the latest set of guidance (List 3) of the Evidence-based Interventions (EBI) Programme. EBI program develops guidance sets (Lists) for tests, treatments, and procedures based on recommendations from the Expert Advisory Committee and NICE assessments. Proposed List 3 covers 17 interventions across a range of medical specialties, including cardiology, ophthalmology, urology, and others. The deadline for comments submission is March 31, 2022.

Read more

18

Jan 2022

In December 2021, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (endobronchial nerve ablation for chronic obstructive pulmonary disease and transanal total mesorectal excision for rectal cancer), two new Medical Technologies Guidance (ClearGuard HD antimicrobial barrier caps, and Endo-SPONGE for treating low rectal anastomotic leak), and one new Medtech Innovation Briefings (FreeO2 automatic oxygen titration). Also, one new clinical guideline was published, and five were updated.

Read more
(we accept only company emails)